We are live on ! Find out more
JSPRW icon

Japer Therapeutics Warrants
JSPRW

20 hedge funds and large institutions have $3.03M invested in Japer Therapeutics Warrants in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more capital invested

Capital invested by funds: $2.51M → $3.03M (+$524K)

23% less funds holding

Funds holding: 26 → 20 (-6)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
20
Holders Change
-6
Holders Change %
-23.08%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$28.4K
2
SCM
Shaolin Capital Management
Florida
+$23.3K
3
HF
HRT Financial
New York
+$19.2K

Top Sellers

Rank Fund Capital Flow
1
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$153K
2
ACM
Altium Capital Management
New York
-$133K
3
AGM
Alpine Global Management
New York
-$42K
4
LA
Linden Advisors
New York
-$29.6K
5
OAC
OMERS Administration Corp
Ontario, Canada
-$17K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
– -$3K -3,729 Closed
1
2

JSPRW Hedge Fund Activity: Q2 2021 in Review

20 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q2 2021, worth a combined $3.03M — up 21% from $2.51M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of JSPRW and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Cowen and Company, opening a new position worth an estimated $28.4K. The largest seller was Picton Mahoney Asset Management, exiting entirely with an estimated $153K sold.

  • 20 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q2 2021, down from 26 in Q1 2021.
  • Funds reported $3.03M of Japer Therapeutics Warrants stock for Q2 2021, up 21% quarter-over-quarter.
  • 1 fund opened new Japer Therapeutics Warrants positions in Q2 2021 and 7 closed out, a net change of -6 holders.
  • The largest Japer Therapeutics Warrants buyer in Q2 2021 was Cowen and Company, an estimated $28.4K added.
  • The largest Japer Therapeutics Warrants seller in Q2 2021 was Picton Mahoney Asset Management, an estimated $153K sold.

Based on aggregated 13F filings for Q2 2021.